NCT00061620 is a Phase 1 clinical trial of Tezacitabine (FMdC) in Hematologic Malignancies, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00061620?

NCT00061620 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00061620?

Interventions in NCT00061620: Tezacitabine (FMdC).

What condition does NCT00061620 study?

NCT00061620 studies Hematologic Malignancies.

Is NCT00061620 still recruiting?

NCT00061620 is currently completed. Last updated 1 November 2018.

Last reviewed 2018-11-01 · How we verify

NCT00061620

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies

Completed Phase 1 Last updated 1 November 2018

What this trial tests

Phase 1 trial testing Tezacitabine (FMdC) in Hematologic Malignancies in 19 participants. Completed in 12 February 2004.

Timeline

6 September 2001

Primary endpoint
12 February 2004

12 February 2004

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	6 September 2001
Primary completion	12 February 2004
Estimated completion	12 February 2004
Sites	1 location across United States

Drugs / interventions tested

Tezacitabine (FMdC) — full drug profile →

Conditions studied

Hematologic Malignancies — all drugs for Hematologic Malignancies →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

15 and older, any sex, with Hematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest dose of Tezacitabine (FMdC) which can be safely given as a continuous infusion by vein to patients with hematologic malignancies. The general safety and effectiveness of this drug will also be studied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hematologic Malignancies

Currently open trials in the same condition.

NCT04546945 — Aberrant Expression of CD56 in Patients With Hematologic Malignancies. · recruiting
NCT06926595 — Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention · Phase 2 · recruiting
NCT07186192 — Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy · Phase 3 · recruiting
NCT07195916 — A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies · Phase 1 · recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00061620 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 1 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00061620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing